An observational study in Rheumatoid Arthritis, sponsored by Vastra Gotaland Region. Status unknown at 1 site in Sweden. Open to participants aged 20 Years and older. Per ClinicalTrials.gov, last updated 2022-05-04.
Sponsored by Vastra Gotaland Region · Observational
To validate the utility of survivin as a biomarker of pharmacological response to therapeutic intervention in rheumatoid arthritis patients.
In a prospective observational study the investigators aim to study the ability of modern antirheumatic treatments to suppress levels of survivin in sera. Rheumatoid arthritis patients scheduled to start new pharmacological treatment will be followed for a period of 6 months. No intervention or influence on choice of treatment will be performed, the decision of new/other medication is entirely made by the patient and their rheumatologist. The study entails addition of survivin analyse (1 vial of sera) before and after start of new treatment. Data concerning survivin levels, disease activity and other clinical parameters before and after start of new treatment will also be analysed. The patients will leave sera for survivin analyse at baseline and 3 and 6 months after start of new treatment.
Rheumatoid arthritis patients
Exclusion Criteria:
Drug: methotrexate · Drug: sulfasalazine · Drug: abatacept · Drug: tocilizumab · Drug: tofacitinib/baricitinib
folate antagonist
Immunomodulatory
Also known as: Salazopyrin
Targeting CTLA-4 (fusion protein composed of the Fc region of the immunoglobulin IgG1 fused to the extracellular domain of CTLA-4)
Also known as: Orencia
IL-6 receptor antagonist
Also known as: RoActemra
JAK inhibitor
Also known as: Xeljanz/Olumiant
Survivin status
Patients with a survivin level of over 0.45 ng/ml are considered to be survivin positive. Patients with survivin levels under 0.45 ng/ml are considered to be survivin negative A change from survivin positive to survivin negative (or vice versa) equals conversion of survivin status.
Time frame: 6 months
Disease activity (DAS28)
Disease activity, DAS28, is calculated using a specific formula based on: * number of painful joints from 28 joints * number of swollen joints from 28 joints * erythrocyte sedimentation rate (ESR) or C reactive protein (CRP) * patient's global assessment of disease activity on a 100 mm visual analogue scale (VAS) DAS thresholds: DAS28 below 3.2: low disease activity DAS28 over 3.2 and under 5.1: moderate disease activity DAS28 above 5.1: high disease activity DAS28 lower than 2.6: remission
Time frame: 6 months
Response to treatment
The EULAR response criteria classify patients as good, moderate, or non-responders, using the change in DAS28 and the level of DAS28 reached. A patient must show a significant change as well as low disease activity to be classified as a good responder. Good responder: DAS28 scores ≤ 3.2 with reductions in DAS28 \>1.2 Moderate responder: DAS28 scores \> 3.2 with reductions in DAS28 \>1.2 Non-responder: reductions in DAS28 ≤ 0.6
Time frame: 6 months
This study is status unknown, as verified in May 2022. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Vastra Gotaland Region